Antimicrobial Drug/Test Joint Development Needs Better Incentives

Stakeholders still need to develop solutions that will allow faster development of susceptibility testing devices, and in turn facilitate prescribing of new antimicrobial drugs.

Puzzle

Drugmakers, devicemakers and regulators appear to have come to a mutual understanding of the barriers each party faces in the development and approval of antimicrobial drugs and antimicrobial susceptibility test (AST) devices, but many questions still remain on how to make AST devices available in a timely manner following approval of a new drug.

Atop the list of issues is the significant lag between approval times of antimicrobial drugs and AST devices, the groups...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Approvals

More from Product Reviews

  • data

    New EU Filings

     
    • By 

    <p>Executive Summary</p> <p>Zanidatamab, Jazz and BeiGene’s investigational treatment for biliary tract cancer, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.</p>

  • data

    EU CHMP Opinions And MAA Updates

     
    • By 

    <p>Executive Summary</p> This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>